NCT00066859 is a Phase 3 clinical trial of Zoloft 50 mg in Depression, sponsored by Wake Forest University Health Sciences.

Who is sponsoring NCT00066859?

NCT00066859 is sponsored by Wake Forest University Health Sciences.

What drugs are being tested in NCT00066859?

Interventions in NCT00066859: Zoloft 50 mg, St. John's Wort 600 mg.

What condition does NCT00066859 study?

NCT00066859 studies Depression, Unspecified Adult Solid Tumor, Protocol Specific.

Is NCT00066859 still recruiting?

NCT00066859 is currently completed. Last updated 9 September 2021.

Last reviewed 2021-09-09 · How we verify

NCT00066859

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sertraline Compared With Hypericum Perforatum (St.John's Wort) in Treating Depression

Completed Phase 3 Last updated 9 September 2021

What this trial tests

Phase 3 trial testing Zoloft 50 mg in Depression in 2 participants. Completed in 1 November 2005.

Timeline

1 March 2004

Primary endpoint
1 April 2005

1 November 2005

Quick facts

Lead sponsor	Wake Forest University Health Sciences
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	supportive care
Enrollment	2
Start date	1 March 2004
Primary completion	1 April 2005
Estimated completion	1 November 2005
Sites	6 locations across United States

Drugs / interventions tested

Zoloft 50 mg — full drug profile →
St. John's Wort 600 mg

Conditions studied

Depression — all drugs for Depression →
Unspecified Adult Solid Tumor, Protocol Specific — all drugs for Unspecified Adult Solid Tumor, Protocol Specific →

Sponsor

Wake Forest University Health Sciences

Who can join

18 and older, any sex, with Depression or Unspecified Adult Solid Tumor, Protocol Specific. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Antidepressants such as sertraline and the herb hypericum perforatum (St. John's wort) may be effective in treating mild to moderate depression. It is not yet known which treatment is more effective in improving depression in patients who have cancer. PURPOSE: This randomized phase III trial is studying how well sertraline works compared to St. John's wort in treating mild to moderate depression in patients with solid tumors.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Antidepressants for the treatment of depression in people with cancer.
Ostuzzi G, Matcham F, Dauchy S, Barbui C, et al · · 2018 · cited 89× · PMID 29683474 · DOI 10.1002/14651858.cd011006.pub3
Antidepressants for the treatment of depression in people with cancer.
Ostuzzi G, Matcham F, Dauchy S, Barbui C, et al · · 2015 · cited 38× · PMID 26029972 · DOI 10.1002/14651858.cd011006.pub2
Antidepressants for the treatment of depression in people with cancer.
Vita G, Compri B, Matcham F, Barbui C, et al · · 2023 · cited 31× · PMID 36999619 · DOI 10.1002/14651858.cd011006.pub4
Twelve Chinese herbal preparations for the treatment of depression or depressive symptoms in cancer patients: a systematic review and meta-analysis of randomized controlled trials.
Li M, Chen Z, Liu Z, Zhang N, et al · · 2019 · cited 15× · PMID 30674300 · DOI 10.1186/s12906-019-2441-8
Enhancing of cerebral Abeta clearance by modulation of ABC transporter expression: a review of experimental approaches.
Loeffler DA. · · 2024 · cited 2× · PMID 38872626 · DOI 10.3389/fnagi.2024.1368200

Verify or expand the search:

Other recruiting trials for Depression

Currently open trials in the same condition.

NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or · Phase 2 · recruiting
NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT07517549 — Sexual Health Education During Pregnancy · NA · recruiting
NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression · NA · recruiting

Other Wake Forest University Health Sciences trials

Trials by the same sponsor.

NCT07474090 — Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial · NA · not yet recruiting
NCT07282444 — A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial · NA · not yet recruiting
NCT06876896 — Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter · NA · recruiting
NCT07227051 — Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity · NA · recruiting
NCT07215624 — Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00066859 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wake Forest University Health Sciences
Last refreshed: 9 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00066859.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing